Hasil Pencarian - Tian Fu Wen

  • Menampilkan 1 - 9 hasil dari 9
Perbaiki Hasil
  1. 1
    Postoperative Low Absolute Lymphocyte Counts may Predict Poor Outcomes of Hepatocellular Carcinoma After Liver Resection

    Postoperative Low Absolute Lymphocyte Counts may Predict Poor Outcomes of Hepatocellular Carcinoma After Liver Resection oleh Ming Wang, Chuan Li, Tian-Fu Wen, Wei Peng, Li-Ping Chen

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Pretransplant prediction of posttransplant survival for liver recipients with benign end-stage liver diseases: a nonlinear model.

    Pretransplant prediction of posttransplant survival for liver recipients with benign end-stage liver diseases: a nonlinear model. oleh Ming Zhang, Fei Yin, Bo Chen, You Ping Li, Lu Nan Yan, Tian Fu Wen, Bo Li

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    A novel model for predicting posthepatectomy liver failure in patients with hepatocellular carcinoma.

    A novel model for predicting posthepatectomy liver failure in patients with hepatocellular carcinoma. oleh Wei Peng, Jia-Wu Li, Xiao-Yun Zhang, Chuan Li, Tian-Fu Wen, Lv-Nan Yan, Jia-Yin Yang

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Scoring selection criteria including total tumour volume and pretransplant percentage of lymphocytes to predict recurrence of hepatocellular carcinoma after liver transplantation.

    Scoring selection criteria including total tumour volume and pretransplant percentage of lymphocytes to predict recurrence of hepatocellular carcinoma after liver transplantation. oleh Chuan Li, Tian-Fu Wen, Lu-Nan Yan, Bo Li, Jia-Ying Yang, Ming-Qing Xu, Wen-Tao Wang, Yong-Gang Wei

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization

    A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization oleh Chang Liu, Lei Li, Wu-sheng Lu, Hua Du, Lu-nan Yan, Tian-fu Wen, Wu-ran Wei, Li Jiang, Ming-qing Xu

    Diterbitkan 2018-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Outcome of using small-for-size grafts in living donor liver transplantation recipients with high model for end-stage liver disease scores: a single center experience.

    Outcome of using small-for-size grafts in living donor liver transplantation recipients with high model for end-stage liver disease scores: a single center experience. oleh HongYu Li, Bo Li, YongGang Wei, LvNan Yan, TianFu Wen, MingQing Xu, WenTao Wang, JiaYin Yang

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Outcomes of patients with benign liver diseases undergoing living donor versus deceased donor liver transplantation.

    Outcomes of patients with benign liver diseases undergoing living donor versus deceased donor liver transplantation. oleh Chuan Li, Kai Mi, Tian fu Wen, Lu nan Yan, Bo Li, Jia ying Yang, Ming qing Xu, Wen tao Wang, Yong gang Wei

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Risk factors for in-hospital mortality of patients with high model for end-stage liver disease scores following living donor liver transplantation

    Risk factors for in-hospital mortality of patients with high model for end-stage liver disease scores following living donor liver transplantation oleh Chuan Li, M.D., Tian-Fu Wen, Lu-Nan Yan, Bo Li, Jia-Ying Yang, Ming-Qing Xu, Wen-Tao Wang, Yong-Gang Wei

    Diterbitkan 2012-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

    Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study oleh Guo‐Ming Shi, Xiao‐Yong Huang, Tian‐Fu Wen, Tian‐Qiang Song, Ming Kuang, Hai‐Bo Mou, Le‐Qun Bao, Hai‐Tao Zhao, Hong Zhao, Xie‐Lin Feng, Bi‐Xiang Zhang, Tao Peng, Yu‐Bao Zhang, Xiang‐Cheng Li, Hong‐Sheng Yu, Yu Cao, Lian‐Xin Liu, Ti Zhang, Wei‐Lin Wang, Jiang‐Hua Ran, Ying‐Bin Liu, Wei Gong, Ming‐Xia Chen, Lian Cao, Yang Luo, Yan Wang, Hui Zhou, Guo‐Huan Yang, Jia Fan, Jian Zhou

    Diterbitkan 2023-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: